Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
09 mai 2024 14h51 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 08h00 HE
|
Phathom Pharmaceuticals
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
09 mai 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
08 mai 2024 16h05 HE
|
Assembly Biosciences, Inc.
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...
SchooLinks Recognized Among America's Best Startup Employers by Forbes and Inc.
08 mai 2024 07h15 HE
|
SchooLinks
Austin, TX, May 08, 2024 (GLOBE NEWSWIRE) -- SchooLinks, the most innovative platform for college and career readiness, is proud to announce its recent achievements in both business growth and...
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
06 mai 2024 06h05 HE
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE
Interstitial Cystitis Drugs Global Market Report 2024, By Drugs (Pentosan Polysulfate Sodium; Dimethyl Sulfoxide), By Type (Oral Therapy; Intravesical Therapy) and By Distribution Channel
06 mai 2024 04h06 HE
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Interstitial Cystitis Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The interstitial cystitis drugs...
Global Migraine Drugs Market Report 2024, By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants), By Route of Administration (Oral, Injectable) and By End-User
06 mai 2024 04h05 HE
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Migraine Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The migraine drugs market size has grown strongly...
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
03 mai 2024 07h00 HE
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1...